A JAMA case series found that a blood-based tau marker was higher in former football players whose autopsies showed advanced chronic traumatic encephalopathy, a finding that may help researchers investigate the disease during life.
Researchers linked blood drawn before death to brain donations and autopsy results from 21 men completed through Oct. 9, 2026. Eighteen had CTE: 16 had high-stage disease, including eight stage III and eight stage IV cases, while two had low-stage disease, one stage I and one stage II. Three participants had no CTE.
Median plasma endogenously cleaved microtubule-binding region tau, or eMTBR-tau, measured 0.021 picograms per milliliter in the high-stage group. The median was 0.001 pg/mL in both the low-stage CTE group and participants without CTE.
The marker also rose with cumulative tau burden measured across 11 brain regions. The reported association estimate was β=0.71, with a 95% confidence interval of 0.38 to 1.05.
Five participants with CTE also had Alzheimer disease neuropathologic change. Their median eMTBR-tau concentration was 0.082 pg/mL, compared with 0.009 pg/mL among 11 participants with high-stage CTE but without that co-pathology.
Plasma phosphorylated tau 217 was associated with Alzheimer disease pathology but not with CTE in the case series. Four participants who had both CTE and Alzheimer disease pathology recorded p-tau217 readings in the positive range.
Alamar Biosciences said the researchers used its NULISAqpcr eMTBR-tau single-plex assay. The company announced the findings Nov. 20 at 8:30 a.m. ET, after the study was published online in JAMA on Nov. 19.
“If our finding is validated, having a biomarker that can accurately detect CTE will open the door to diagnosis when people are still living and to an entirely new phase of research, including clinical trials where we can start to focus on treatment,” said Michael Alosco, a Boston University professor of neurology and the study’s corresponding author.
CTE is associated with repeated head impacts and is characterized by perivascular accumulation of hyperphosphorylated tau. It cannot currently be confirmed during life because no validated biomarker for its brain pathology has been established.
The researchers said the sample was small and drawn from a specialized research center, limiting how broadly the findings can be applied. They called for larger autopsy cohorts and clinical validation studies to determine accuracy, specificity and useful thresholds. They said the assay remains a research method and is not available as a clinical diagnostic.
The findings add to earlier research on CTE pathology among former NFL players, but they do not establish a test for diagnosing the disease in living patients.



